SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera

This publication has 70 references indexed in Scilit:

• Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
  Blood, 2013
• Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
  Leukemia, 2013
• A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
  British Journal of Haematology, 2013
• Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
  New England Journal of Medicine, 2013
• Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
  Blood, 2012
• A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
  British Journal of Haematology, 2010
• Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
  Blood, 2009
• The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
  Leukemia, 2007
• Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
  Leukemia, 2007
• Vascular and Neoplastic Risk in a Large Cohort of Patients With Polycythemia Vera
  Journal of Clinical Oncology, 2005